Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 60 - Any |
| Updated: | 10/14/2017 |
| Start Date: | December 2009 |
| End Date: | October 2010 |
A Study To Evaluate The Persistence Of The Antibody Response Elicited By 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Adults Who Have Previously Been Vaccinated With Either 2 Doses Of 13vPnC Or 13vPnC And 23-Valent Pneumococcal Polysaccharide Vaccine In Different Sequential Order In Study 6115A1-3010 Or 6115A1 3005
The purpose of this study is to evaluate the levels of antibodies 1 year after receiving the
second vaccine dose in two groups of adults over the age of 60: (1) those who have previously
received 2 doses of 13-valent pneumococcal conjugate vaccine (13vPnC) and (2) those who have
previously received 1 dose of 13vPnc and 1 dose of 23-valent pneumococcal polysaccharide
vaccine (23vPS). This study will also assess whether the use of the 2 vaccines, 13vPnC and
23vPS, administered in different sequential order results in different prolonged antibody
levels. This study is limited to individuals who participated in either study 6115A1-3010
(NCT00574548) or 6115A1-3005 (NCT00546572).
second vaccine dose in two groups of adults over the age of 60: (1) those who have previously
received 2 doses of 13-valent pneumococcal conjugate vaccine (13vPnC) and (2) those who have
previously received 1 dose of 13vPnc and 1 dose of 23-valent pneumococcal polysaccharide
vaccine (23vPS). This study will also assess whether the use of the 2 vaccines, 13vPnC and
23vPS, administered in different sequential order results in different prolonged antibody
levels. This study is limited to individuals who participated in either study 6115A1-3010
(NCT00574548) or 6115A1-3005 (NCT00546572).
Inclusion Criteria:
- Only study volunteers who received both assigned vaccinations at visit 1 and visit 4
when they participated in either study 6115A1-3010 (NCT00574548) or 6115A1-3005
(NCT00546572)
Exclusion Criteria:
- Vaccination with any licensed or experimental pneumococcal vaccine since being
enrolled in the 6115A1-3005 (NCT00546572) or 6115A1-3010 (NCT00574548) study (other
than study vaccines permitted in 6115A1-3010 or 6115A1-3005)
We found this trial at
28
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials